Targeting SDF-1 in multiple myeloma tumor microenvironment

被引:35
作者
Bouyssou, Juliette M. C. [1 ,2 ]
Ghobrial, Irene M. [1 ]
Roccaro, Aldo M. [1 ]
机构
[1] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, 450 Brookline Ave,HIM 246, Boston, MA 02215 USA
[2] INSERM, UMR 1163, Lab Cellular & Mol Mech Hematol Disorders & Thera, Paris, France
关键词
SDF-1; CXCR4; Multiple myeloma; Microenvironment; Bone marrow; STROMAL-DERIVED FACTOR-1-ALPHA; BONE-MARROW MICROENVIRONMENT; CELL-ADHESION; MURINE MODEL; IN-VITRO; MIGRATION; EXPRESSION; CXCR4; AXIS; RECEPTOR;
D O I
10.1016/j.canlet.2015.11.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM) is a type of B-cell malignancy that remains incurable to date. The bone marrow (BM) microenvironment plays a crucial role in MM progression. The chemokine SDF-1 (CXCL12) is an important actor of the BM microenvironment that has the ability to regulate numerous processes related to its malignant transformation during MM development. The activity of SDF-1 is mainly mediated by its specific receptor CXCR4, which is expressed at the surface of MM cells and various other BM cell types. Current treatments available for MM patients mainly target tumor cells but have limited effects on the BM microenvironment. In this context, SDF-1 and CXCR4 represent ideal targets for the normalization of the MM-supportive BM microenvironment. The present review focuses on the activity of SDF-1 in the MM BM microenvironment and the current efforts carried out to target the SDF-1/CXCR4 axis for treatment of MM. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:315 / 318
页数:4
相关论文
共 56 条
[21]   Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells [J].
Kim, Seong-Woo ;
Kim, Ha-Yon ;
Lee, Hyo-Jin ;
Yun, Hwan-Jung ;
Kim, Samyong ;
Jo, Deog-Yeon .
LEUKEMIA & LYMPHOMA, 2009, 50 (07) :1163-1173
[22]   BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies [J].
Kuhne, Michelle R. ;
Mulvey, Tanya ;
Belanger, Blake ;
Chen, Sharline ;
Pan, Chin ;
Chong, Colin ;
Cao, Fei ;
Niekro, Wafa ;
Kempe, Tom ;
Henning, Karla A. ;
Cohen, Lewis J. ;
Korman, Alan J. ;
Cardarelli, Pina M. .
CLINICAL CANCER RESEARCH, 2013, 19 (02) :357-366
[23]   Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients [J].
Kumar, S. K. ;
Dispenzieri, A. ;
Lacy, M. Q. ;
Gertz, M. A. ;
Buadi, F. K. ;
Pandey, S. ;
Kapoor, P. ;
Dingli, D. ;
Hayman, S. R. ;
Leung, N. ;
Lust, J. ;
McCurdy, A. ;
Russell, S. J. ;
Zeldenrust, S. R. ;
Kyle, R. A. ;
Rajkumar, S. V. .
LEUKEMIA, 2014, 28 (05) :1122-1128
[24]   Bone Marrow Microenvironment in Multiple Myeloma Progression [J].
Manier, S. ;
Sacco, A. ;
Leleu, X. ;
Ghobrial, I. M. ;
Roccaro, A. M. .
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012,
[25]   Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma [J].
Martin, Sally K. ;
Dewar, Andrea L. ;
Farrugia, Amanda N. ;
Horvath, Noemi ;
Gronthos, Stan ;
To, L. Bik ;
Zannettino, Andrew C. W. .
CLINICAL CANCER RESEARCH, 2006, 12 (23) :6973-6977
[26]   Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells [J].
Martin, Sally K. ;
Diamond, Peter ;
Williams, Sharon A. ;
To, Luen Bik ;
Peet, Daniel J. ;
Fujii, Nobutaka ;
Gronthos, Stan ;
Harris, Adrian L. ;
Zannettino, Andrew C. W. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05) :776-784
[27]  
Menu E, 2006, HAEMATOLOGICA, V91, P605
[28]   Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1 [J].
Mirandola, L. ;
Apicella, L. ;
Colombo, M. ;
Yu, Y. ;
Berta, D. G. ;
Platonova, N. ;
Lazzari, E. ;
Lancellotti, M. ;
Bulfamante, G. ;
Cobos, E. ;
Chiriva-Internati, M. ;
Chiaramonte, R. .
LEUKEMIA, 2013, 27 (07) :1558-1566
[29]   Expression and function of chemokine receptors in human multiple myeloma [J].
Möller, C ;
Strömberg, T ;
Juremalm, M ;
Nilsson, K ;
Nilsson, G .
LEUKEMIA, 2003, 17 (01) :203-210
[30]  
Moschetta M., 2014, 56 AM SOC HEM ANN M, P4719